Compare Merck & Co., Inc. (MRK) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs SpaceX — how do they compare? Merck & Co., Inc. trades at $126.19 (market cap $307.25B), while SpaceX trades at $123.46 (market cap $1.58T). The key difference: SpaceX is far larger — about 5.1× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays a 2.73% dividend while SpaceX pays none. Which is the better fit depends on your goals.
| MRK | SPCX | |
|---|---|---|
Market Cap | $307.25B | $1.58T |
Sector | Health | Technology |
52-Week High | $129.52 | $202.09 |
52-Week Low | $77.60 | $119.85 |
Enterprise Value | $350.66B | $1.59T |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.
The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.
SPCX trades at $119.85, down 3.34% today and 45% below its post-IPO high, with a bearish technical signal despite oversold RSI readings. The company reported Q1 2026 EPS of -$1.19, missing estimates by 260%, while revenue grew to $18.67B in 2025. SpaceX faces significant valuation concerns with a P/S of 84 and negative profitability metrics, though analyst consensus remains 100% buy-rated with a $237.78 price target representing 98% upside potential.
The stock presents high-risk/high-reward potential with strong institutional support but faces near-term headwinds from August lockup expirations and persistent losses. Long-term growth depends on Starlink expansion and AI contract wins, though current fundamentals don't justify the premium valuation. Investors must weigh analyst optimism against cash burn and execution risks in the competitive space sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
